HOME OUR COMPANY TECHNOLOGY & INNOVATION R&D PORTFOLIO INVESTORS PARTNERSHIPS NEWS & EVENTS CAREERS CONTACT Nanobodies Competitive Features Ablynx >Technology & innovation >Nanobodies Competitive Features Due to their small size and unique structure, Nanobodies are ideal building blocks for the generation of novel biological drugs with multiple advantages: Ability to bind multiple targets with one therapeutic Nanobody molecule. These therapeutic molecules may contain Nanobody building blocks combined with each other (up to 7), or be combined with other protein domains or with other molecules or drugs. Multi-specific (binding different targets; currently 2 bi-specific Nanobodies in the clinic), multivalent (binding identical targets; currently 2 Nanobodies in the clinic) and bi-paratopic (binding different epitopes on the same target) Nanobody molecules have been successfully produced and their potential therapeutic effect demonstrated. The different Nanobody building blocks are linked together with Glycine-Serine linkers with flexible lengths. CASE STUDIES Mix and Match Presentation: "Nanobodies as a Versatile Approach for Developing Next Generation Immunotherapies" Poster presentation: by Boehringer Ingelheim: "Dual targeting of angiogenesis pathways: combined blockade of VEGF and Ang2 signalling" Presentation: "Nanobodies as a versatile and clinically validated approach for multi-specific therapeutics" Presentation: "Bi-specific Nanobodies with enhanced cell specificity" Presentation: "Strategies and Challenges in Analytical Testing of Nanobody-Based Multi-specifics" Cell- /tissue homing Presentation: "The Nanobody platform: opportunity for next generation T-cell recruitment" Challenging and intractable targets Presentation: "Ion channel modulating Nanobodies - 2 in vitro and in vivo case studies" Poster: "Characterization of anti-Kv1.3 Nanobodies and activity in inflammatory model systems" Poster: "Formatting flexibility of Nanobodies is ideally suited for ion channels: Kv1.3 case study" Presentation: "Nanobodies against difficult targets: Tackling ion channels” Poster: "Development of highly potent and selective anti-Kv1.3 Nanobodies that operate through allosteric modulation" Alternative delivery routes Poster: "Non-clinical safety assessment of ALX-0171, anti-RSV Nanobody intended for clinical administration through inhalation" Manufacturing Presentation: "Double digit-titers and high product quality of Nanobodies" 2015 - 2018 © Ablynx Disclaimer Sitemap Our Company Technology & innovation R&D portfolio Investors Partnerships News & events Careers Contact